Mariner
ALDX icon

Mariner’s Aldeyra Therapeutics ALDX Stock Holding History

Mariner’s Portfolio ALDX Stock Details ALDX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$192K Sell
90,339
-1,531
-2% -$2.63K ﹤0.01% 3166
2026
Q1 		$155K Buy
91,870
+68,994
+302% +$302K ﹤0.01% 3228
2025
Q4 		$118K Sell
22,876
-6,970
-23% -$35.8K ﹤0.01% 3298
2025
Q3 		$156K Buy
29,846
+7,433
+33% +$38.8K ﹤0.01% 3261
2025
Q2 		$85.8K Buy
+22,413
New +$57.9K ﹤0.01% 3271

Other funds holding ALDX

KCM
Knoll Capital Management Miami, Florida $179M AUM 63.61% 1-Year Est. Return
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return
KCM
Kingdon Capital Management New York $976M AUM 66.76% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
D.E. Shaw & Co
D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return
Marshall Wace
Marshall Wace London, United Kingdom $127B AUM 46.06% 1-Year Est. Return
6CM
683 Capital Management New York $2.04B AUM 94.26% 1-Year Est. Return
Jane Street
Jane Street New York $1.21T AUM 78.12% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Qube Research & Technologies (QRT)
Qube Research & Technologies (QRT) London, United Kingdom $108B AUM 37.29% 1-Year Est. Return

Mariner's ALDX Position: Q2 2026 in Review

Mariner reduced its Aldeyra Therapeutics (ALDX) stake by 1.7% in Q2 2026, selling an estimated $2.63K and leaving 90,339 shares worth $192K. The position accounts for ﹤0.01% of the portfolio, ranked #3166.

Mariner first reported a position in ALDX in Q2 2025 and has held it in 5 quarters since. 108 funds tracked by Wall St. Rank hold ALDX as of Q2 2026.

  • Mariner held 90,339 shares of Aldeyra Therapeutics worth $192K as of Q2 2026.
  • Mariner sold 1,531 Aldeyra Therapeutics shares in Q2 2026, an estimated $2.63K.
  • Aldeyra Therapeutics made up ﹤0.01% of Mariner's portfolio in Q2 2026, its #3166 holding.
  • Mariner first reported a position in Aldeyra Therapeutics in Q2 2025 and has held it in 5 quarters since.
  • 108 funds tracked by Wall St. Rank held Aldeyra Therapeutics as of Q2 2026.

Based on Mariner's 13F filing for Q2 2026, filed 13 Aug 2026.